Abstract
Purpose: The aim of this study was to investigate the influence of androgen deprivation therapy (ADT) on the progression of non-alcoholic fatty liver disease (NAFLD) in patients with prostate cancer (PCa) by evaluation of hepatic steatosis on computed tomography (CT). Methods: The study included 77 PCa patients who underwent abdominal CT at baseline and after 6 months of ADT. The degree of hepatic steatosis was evaluated according to the attenuation value for liver parenchyma (CTLP), the attenuation ratio for liver and spleen (LSratio), and the difference in attenuation between LS (LSdif). The associations between these 3 indices and various metabolic syndrome-related factors were analyzed. Results: The number of NAFLD patients increased from 9 (11.6%) at baseline to 16 (20.7%) after ADT. The CTLP, LSratio, and LSdif values were significantly lower after ADT than before (p < 0.05). There were significant correlations between the percent change in CTLP and the percent change in HbA1c, between the percent change in LSratio and the percent change in abdominal circumference, and between the percent change in LSdif and the percent change in BMI. Conclusions: Six months of ADT was associated with significant progression of NAFLD in PCa patients. This progression was strongly correlated with changes in HbA1c, abdominal circumference, and BMI.
References
1.
Vargas
A
, Machado
RD
, Filho
DI
, Paiva
CE
, Dos Reis
RB
, Tobias-Machado
M
, et al. LHRH analog therapy is associated with worse metabolic side effects than bilateral orchiectomy in prostate cancer
. World J Urol
. 2016
Dec
;34
(12
):1621
–8
.
[PubMed]
0724-49832.
Mitsuzuka
K
, Kyan
A
, Sato
T
, Orikasa
K
, Miyazato
M
, Aoki
H
, et al.; Tohoku Evidence-Based Medicine Study Group
; Michinoku Urological Cancer Study Group
. Influence of 1 year of androgen deprivation therapy on lipid and glucose metabolism and fat accumulation in Japanese patients with prostate cancer
. Prostate Cancer Prostatic Dis
. 2016
Mar
;19
(1
):57
–62
.
[PubMed]
1365-78523.
Dockery
F
, Bulpitt
CJ
, Agarwal
S
, Donaldson
M
, Rajkumar
C
. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia
. Clin Sci (Lond)
. 2003
Feb
;104
(2
):195
–201
.
[PubMed]
0143-52214.
Salvador
C
, Planas
J
, Agreda
F
, Placer
J
, Trilla
E
, Lopez
MA
, et al. Analysis of the lipid profile and atherogenic risk during androgen deprivation therapy in prostate cancer patients
. Urol Int
. 2013
;90
(1
):41
–4
.
[PubMed]
0042-11385.
Smith
MR
, Lee
H
, Nathan
DM
. Insulin sensitivity during combined androgen blockade for prostate cancer
. J Clin Endocrinol Metab
. 2006
Apr
;91
(4
):1305
–8
.
[PubMed]
0021-972X6.
Byrne
CD
, Targher
G
. NAFLD: a multisystem disease
. J Hepatol
. 2015
Apr
;62
(1
Suppl
):S47
–64
.
[PubMed]
0168-82787.
Gild
P
, Cole
AP
, Krasnova
A
, Dickerman
BA
, von Landenberg
N
, Sun
M
, et al. Liver disease in men undergoing androgen deprivation therapy for prostate cancer
. J Urol
. 2018
Sep
;200
(3
):573
–81
.
[PubMed]
0022-53478.
Lee
DH
. Imaging evaluation of non-alcoholic fatty liver disease: focused on quantification
. Clin Mol Hepatol
. 2017
Dec
;23
(4
):290
–301
.
[PubMed]
2287-27289.
Zhang
Y
, Wang
C
, Duanmu
Y
, Zhang
C
, Zhao
W
, Wang
L
, et al. Comparison of CT and magnetic resonance mDIXON-Quant sequence in the diagnosis of mild hepatic steatosis
. Br J Radiol
. 2018
Nov
;91
(1091
):20170587
.
[PubMed]
0007-128510.
van Werven
JR
, Marsman
HA
, Nederveen
AJ
, Smits
NJ
, ten Kate
FJ
, van Gulik
TM
, et al. Assessment of hepatic steatosis in patients undergoing liver resection: comparison of US, CT, T1-weighted dual-echo MR imaging, and point-resolved 1H MR spectroscopy
. Radiology
. 2010
Jul
;256
(1
):159
–68
.
[PubMed]
0033-841911.
Armstrong
MJ
, Houlihan
DD
, Bentham
L
, Shaw
JC
, Cramb
R
, Olliff
S
, et al. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort
. J Hepatol
. 2012
Jan
;56
(1
):234
–40
.
[PubMed]
0168-827812.
Yu
AH
, Duan-Mu
YY
, Zhang
Y
, Wang
L
, Guo
Z
, Yu
YQ
, et al. Correlation between non-alcoholic fatty liver disease and visceral adipose tissue in non-obese Chinese adults: a CT evaluation
. Korean J Radiol
. 2018
Sep-Oct
;19
(5
):923
–9
.
[PubMed]
1229-692913.
Sjöström
L
, Kvist
H
, Cederblad
A
, Tylén
U
. Determination of total adipose tissue and body fat in women by computed tomography, 40K, and tritium
. Am J Physiol
. 1986
Jun
;250
(6 Pt 1
):E736
–45
.
[PubMed]
0002-951314.
Kim
S
, Kwon
H
, Park
JH
, Cho
B
, Kim
D
, Oh
SW
, et al. A low level of serum total testosterone is independently associated with nonalcoholic fatty liver disease
. BMC Gastroenterol
. 2012
Jun
;12
(1
):69
.
[PubMed]
1471-230X15.
Yim
JY
, Kim
J
, Kim
D
, Ahmed
A
. Serum testosterone and non-alcoholic fatty liver disease in men and women in the US
. Liver Int
. 2018
Nov
;38
(11
):2051
–9
.
[PubMed]
1478-322316.
Sakr
HF
, Hussein
AM
, Eid
EA
, AlKhateeb
M
. Possible mechanisms underlying fatty liver in a rat model of male hypogonadism: A protective role for testosterone
. Steroids
. 2018
Jul
;135
:21
–30
.
[PubMed]
0039-128X17.
Dai
R
, Yan
D
, Li
J
, Chen
S
, Liu
Y
, Chen
R
, et al. Activation of PKR/eIF2α signaling cascade is associated with dihydrotestosterone-induced cell cycle arrest and apoptosis in human liver cells
. J Cell Biochem
. 2012
May
;113
(5
):1800
–8
.
[PubMed]
0730-231218.
Zhang
YN
, Fowler
KJ
, Hamilton
G
, Cui
JY
, Sy
EZ
, Balanay
M
, et al. Liver fat imaging-a clinical overview of ultrasound, CT, and MR imaging
. Br J Radiol
. 2018
Sep
;91
(1089
):20170959
.
[PubMed]
0007-1285© 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
